Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Composite Lymphoma 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 196pembrolizumab 188Carboplatin 163Biopsy 130Cisplatin 129Nivolumab 121Paclitaxel 110Cyclophosphamide 107Radiotherapy 101Gemcitabine 96Dexamethasone 89durvalumab 85atezolizumab 71Rituximab 66Radiation 65Lenalidomide 64Doxorubicin 64Pemetrexed 61Bevacizumab 59Etoposide 56Docetaxel 55olaparib 53Ipilimumab 51Taxes 48Prednisone 48Fluorouracil 47venetoclax 46Cytarabine 46Vincristine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × ALX148 × 90 days × Clear all
NCT05787639 2026-05-19

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

University of California, San Diego

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Oropharyngeal Neoplasms

NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡